David Moliterno is a Cardiology physician affiliated with University of Kentucky. OpenAlex indexes 413 publications with 23,818 citations (h-index 46). By OpenAlex citation count, this profile ranks in the top 10% of Cardiovascular Disease profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Gill Heart Institute 800 Rose St
G100
Lexington, KY 405360093
Telephone
859-323-0295Registry record last updated 24 Jan 2019.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Research & Development, LLCProgram year20257 payments$39,389openpaymentsdata.cms.gov ↗
- Janssen Research & Development, LLCProgram year20245 payments$17,218openpaymentsdata.cms.gov ↗
- Janssen Research & Development, LLCProgram year20235 payments$22,027openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
83.8%Beta blocker15.5%Metoprolol Succinate58%Metoprolol Tartrate42%Part D<11 patientsCalcium channel blocker11.7%Amlodipine Besylate56%Diltiazem 24hr Er (Cd)44%Part D<11 patients+ 8 more classes in this area
Blood & clotting
12.4%Factor Xa inhibitor8.3%Eliquis100%Part D≥11 patientsVitamin K antagonist4.1%Warfarin Sodium100%Part D<11 patientsMetabolism & gastrointestinal
3.8%SGLT2 inhibitor3.8%Jardiance100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention
Circulation Cardiovascular Interventions
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Dipaola
University of Kentucky
Darwin Conwell, MD
University of Kentucky
Phillip Tibbs
University of Kentucky
Victor Ferraris, MD
University of Kentucky
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”